Continuation Electroconvulsive Therapy vs Pharmacotherapy for Relapse Prevention in Major Depression
Depression
Pharmacotherapy
DOI:
10.1001/archpsyc.63.12.1337
Publication Date:
2006-12-04T21:07:51Z
AUTHORS (17)
ABSTRACT
<h3>Background</h3> Although electroconvulsive therapy (ECT) has been shown to be extremely effective for the acute treatment of major depression, it never systematically assessed as a strategy relapse prevention. <h3>Objective</h3> To evaluate comparative efficacy continuation ECT (C-ECT) and combination lithium carbonate plus nortriptyline hydrochloride (C-Pharm) in prevention depressive relapse. <h3>Design</h3> Multisite, randomized, parallel design, 6-month trial performed from 1997 2004. <h3>Setting</h3> Five academic medical centers their outpatient psychiatry clinics. <h3>Patients</h3> Two hundred one patients with Structured Clinical Interview for<i>DSM-IV–</i>diagnosed unipolar depression who had remitted course bilateral ECT. <h3>Interventions</h3> Random assignment 2 groups receiving either C-ECT (10 treatments) or C-Pharm 6 months. <h3>Main Outcome Measure</h3> Relapse compared between groups. <h3>Results</h3> In group, 37.1% experienced disease relapse, 46.1% continued have remission at study end, 16.8% dropped out study. 31.6% 46.3% remission, 22.1% Both Kaplan-Meier Cox proportional hazards regression analyses indicated no statistically significant differences overall survival curves time Mean ± SD group was 9.1 7.0 weeks 6.7 4.6 (<i>P</i> = .13). proportions significantly lower than historical placebo control similarly designed <h3>Conclusions</h3> were superior control, but both limited efficacy, more half experiencing dropping Even strategies mood disorders are urgently needed.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (0)
CITATIONS (352)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....